Open access
Sep 2026
HER2-Targeted AIE Nanotheranostics Overcome SHR-A1811 Resistance via Immunogenic Pyroptosis and Tumor-Associated Macrophage Reprogramming in Breast Cancer.
Antibody-drug conjugates (ADCs) have revolutionized HER2-positive breast cancer treatment, yet resistance to next-generation agents such as SHR-A1811 (trastuzumab rezetecan) remains a major challenge arising from poor intratumoral delivery, enhanced DNA damage repair, and an immunosuppressive tumor microenvironment (TM...
Xiao-Hong Liu, Ni-Sha Wu, Zai-Hui Peng et al.
· Small · 0 citations